Immunotherapy

CAR T-Cell Therapy Associated with Unique, Acute Adverse Events Requiring Vigilant Monitoring

Wayne Kuznar

May 2019, Vol 9, No 5 - Immunotherapy

Chimeric antigen receptor (CAR) T-cell therapy is associated with unique adverse events that require vigilant monitoring, aggressive care, and specialized management. Marco L. Davila, MD, PhD, Medical Oncologist, Blood and Marrow Transplant and Cellular Immunotherapy Program, Moffitt Cancer Center, Tampa, FL, provided an overview of this topic at the 2019 ASCO-SITC Clinical Immuno-­Oncology Symposium. [ Read More ]

Adjuvant Therapy with Durvalumab, a Checkpoint Inhibitor, Shows Promise in Advanced Esophageal Cancer

Wayne Kuznar

April 2019, Vol 9, No 4 - Immunotherapy

Adjuvant treatment with durvalumab (Imfinzi), a checkpoint inhibitor, in patients with residual disease after trimodal therapy for advanced esophageal or gastroesophageal junction (GEJ) adenocarcinoma was associated with a 79% 1-year relapse-free survival rate in a phase 2 clinical trial. Historically, the 1-year relapse rate has been 50% in patients with GEJ carcinoma who do not achieve a pathologic complete response with trimodal therapy, even with additional chemotherapy, said Hirva Mamdani, MD, Medical Oncology, Karmanos Cancer Institute/Wayne State University, Detroit, MI, at the 2019 Gastrointestinal Cancers Symposium. [ Read More ]

Durable Responses to CAR T-Cell Therapy in B-Cell Lymphomas

Phoebe Starr

March 2019, Vol 9, No 3 - Immunotherapy

Longer-term follow-up of 2 large pivotal clinical trials in B-cell malignancies has demonstrated continuing remissions after chimeric antigen ­receptor (CAR) T-cell therapy: the ELIANA study in pediatric patients and young adults with relapsed or refractory B-acute lymphoblastic leukemia (B-ALL) and the JULIET study in adult patients with diffuse large B-cell lymphoma (DLBCL). Both updates were presented at a press conference at ASH 2018. [ Read More ]

Explosive Development of BCMA CAR T-Cell Therapy for Multiple Myeloma

Phoebe Starr

February 2019, Vol 9, No 2 - Immunotherapy

A dizzying array of new chimeric antigen receptor (CAR) T-cell therapies targeting the B-cell maturation antigen (BCMA) designed specifically for the treatment of multiple myeloma was presented at the 2018 American Society of Hematology (ASH) annual meeting. BCMA-targeted CAR T-cell therapies are designed to improve T-cell persistence, depth of response, and tolerability. Response rates reported at ASH 2018 range from 70% to 100%, depending on the patient population and the use of previous regimens. [ Read More ]

Nivolumab-Ipilimumab Combination Highly Active in Metastatic MSI-H or dMMR Colorectal Cancer

Wayne Kuznar

December 2018, Vol 8, No 12 - Immunotherapy

The combination of immunotherapy with nivolumab (Opdivo) and ipilimumab (Yervoy) may soon represent a new first-line treatment option in patients with early-stage metastatic colorectal cancer (CRC) associated with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) tumors. Two studies presented at the ESMO 2018 Congress demonstrated the efficacy of this combination in this patient population. [ Read More ]

Investigational CAR T-Cell Therapy, bb2121, Shows Durable Responses in Relapsed or Refractory Multiple Myeloma

Wayne Kuznar

November 2018, Vol 8, No 11 - Immunotherapy

The second-generation chimer­ic antigen receptor (CAR) T-cell therapy bb2121, engineered to target B-cell maturation antigen (BCMA), a protein on the surface of certain myeloma cells, displayed continuing efficacy and safety in an update of a phase 1 clinical trial in patients with relapsed or refractory multiple myeloma, according to data presented at ASCO 2018. Currently, no CAR T-cell therapy has been approved for patients with multiple myeloma. [ Read More ]